trial

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

NCTId NCT00588731
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 41 (actual)
Sponsored by Yale University
Primary completion 2013-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
41 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-02
Primary completion
2013-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cannabidiol

Sponsors

Yale UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Mohini Ranganathan, M.D.Principal Investigator

Sites

1 total
New Haven, United States

Linked catalysts

1
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia — primary completion2013-12

Facts & assertions

4 sourced
Enrollment
41
Phase
PHASE2
Primary Completion Date
2013-12
Status
COMPLETED
relationships
The graph out of here
drug
Cannabidiol
drug
lead_sponsor
Yale University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Mohini Ranganathan, M.D.
person